CG Oncology (NASDAQ:CGON) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of CG Oncology (NASDAQ:CGON - Free Report) in a research note released on Monday,Benzinga reports. They currently have a $75.00 price target on the stock.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. Scotiabank started coverage on CG Oncology in a research note on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 target price on the stock. TD Cowen assumed coverage on CG Oncology in a report on Tuesday, January 7th. They issued a "buy" rating on the stock. Finally, Morgan Stanley reissued an "overweight" rating and set a $55.00 price objective on shares of CG Oncology in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, CG Oncology currently has an average rating of "Buy" and a consensus price target of $57.70.

CG Oncology Trading Up 4.7 %

Shares of NASDAQ:CGON traded up $1.31 during mid-day trading on Monday, reaching $29.05. The company had a trading volume of 1,160,711 shares, compared to its average volume of 788,384. The company's 50-day moving average price is $23.68 and its 200-day moving average price is $29.01. CG Oncology has a one year low of $14.80 and a one year high of $46.99. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -20.46 and a beta of 1.24.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The business had revenue of $0.46 million during the quarter, compared to analysts' expectations of $0.11 million. On average, research analysts anticipate that CG Oncology will post -1.31 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction on Monday, April 28th. The shares were sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Hedge Funds Weigh In On CG Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of CG Oncology during the 4th quarter valued at approximately $41,000. CWM LLC raised its stake in CG Oncology by 3,957.7% during the first quarter. CWM LLC now owns 2,110 shares of the company's stock valued at $52,000 after purchasing an additional 2,058 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in CG Oncology during the fourth quarter valued at $68,000. GAMMA Investing LLC lifted its position in CG Oncology by 1,051.0% during the first quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock valued at $56,000 after purchasing an additional 2,102 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of CG Oncology in the 4th quarter worth $100,000. Institutional investors own 26.56% of the company's stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.